Dr. Michael J. Slade, MD
Medical Oncology (Medical Oncology Physician)
1 Barnes Jewish Hospital Plz, Div Im Bone Marrow Transplant
Saint Louis, MO 63110
- Medicare participating
At a glance
- Medical school
- Washington University School of Medicine (2017)
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 280
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Medical school: Washington University School of Medicine
- 2017Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MO license 2019002820 -
Internal Medicine Physician
MO license 2019002820
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- Barnes-Jewish West County Hospital Creve Coeur, MO
- Memorial Hospital Belleville, IL
- Christian Hospital Northeast Saint Louis, MO
- Barnes-Jewish St Peters Hospital Saint Peters, MO
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 280
- Services billed
- 40,158
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 820 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 190 | 14 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 171 | 31 |
| Established patient office or other outpatient visit, 30-39 minutes | 62 | 45 |
| Administration of chemotherapy into vein, 1 hour or less | 58 | 36 |
| Injection of drug or substance under skin or into muscle | 52 | 38 |
| Injection of additional new drug or substance into vein | 39 | 23 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 29 | 27 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 25 | 15 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 24 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Revlimid (lenalidomide) | 152 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Saint Louis, MO | 95 |
| Lenalidomide | 87 |
| Oxycodone Hcl Other prescribers in Saint Louis, MO | 53 |
| Gabapentin Other prescribers in Saint Louis, MO | 46 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Saint Louis, MO | 38 |
| Eliquis (apixaban) Other prescribers in Saint Louis, MO | 31 |
| Pomalyst (pomalidomide) | 26 |
| Omeprazole Other prescribers in Saint Louis, MO | 25 |
| Prochlorperazine Maleate Other prescribers in Saint Louis, MO | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $1,427 in total to this clinician.
| Legend Biotech USA Inc. | $1,281 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $146 |
| Consulting Fee | $1,281 |
|---|---|
| Food and Beverage | $146 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Legend Biotech USA Inc. May 7, 2025 | Consulting Fee CARVYKTI · Oncology | $1,281 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 7 companies. The companies reported $3,565,676 in research payments for these studies, mostly to the institutions running them.
- Measurable residual diseaseguided posttransplant elranatamab maintenance
Pfizer Inc. - BITE & CART
Menarini Silicon Biosystems, Inc. - A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Celgene Corporation - A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Beone Medicines Ltd. · Recruiting · NCT04973605 - Randomized, open-label, Phase 3 trial to evaluate efficacy and safety of ide-cel with lenalidomide maintenance (Arm A) versus lenalidomide maintenance therapy (Arm B) in adult NDMM patients with suboptimal response af…
Celgene Corporation - Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed o…
AbbVie Inc. - A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
E.r. Squibb & Sons, L.l.c. - A Modular Phase I IIOpenlabelMulticenterStudytoEvaluatetheSafetyTolerabilityPharmacokineticsImmunogenicityPharmacodynamicsandPreliminaryEfficacyofAZD0305asMonotherapyorinCombinationwithAnticancerAgentinParticipantswit…
AstraZeneca Pharmaceuticals LP - Randomized, open-label, Phase 3 trial to evaluate efficacy and safety of ide-cel with lenalidomide maintenance (Arm A) versus lenalidomide maintenance therapy (Arm B) in adult NDMM patients with suboptimal response af…
E.r. Squibb & Sons, L.l.c. - Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commercial Release
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.